Medtronic Tweaks its New Pain Pump System

FDA approved a new clinician programmer for use with Medtronic's SynchroMed II intrathecal drug delivery system, an implantable pump that provides targeted drug delivery for patients suffering from chronic pain and severe spasticity. The new technology was designed to simplify therapy management for clinicians by providing them with visual tools and intuitive workflows. The SynchroMed II clinician programmer is a new application that can be used on a tablet and features visual enhancements for a side-by-side comparison of therapy changes. The new app also communicates wirelessly to the SynchroMed II pump with automated calculations to ensure accuracy and improve programming confidence. Charlie Covert, vice president and general manager of targeted drug delivery for Medtronic pain therapies, said the new drug delivery system was specifically designed to be an intuitive and easy-to-use platform to help clinicians safely and effectively treat patients, without the need for dangerous opioids. “Our new clinician programmer follows a series of recent SynchroMed II pump design changes, and was developed with patient safety in mind,” he said. “Our goal was to make it intuitive and simple for clinicians to confidently tailor treatments to best meet patients’ needs. The ability to assist with decreasing the need for systemic opioids is critical, and Medtronic is committed to improving the lives of patients with chronic pain and severe spasticity through continuous innovation a...
Source: MDDI - Category: Medical Devices Authors: Tags: Implants Source Type: news